[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"ovulation-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:ovulation-disorder":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100053696","menstrual-cycle-symptoms-and-female-health-100053696",false,"NCT07699224","Menstrual Cycle Symptoms and Female Health","Prevalence of Subclinical Ovulatory Disturbances and Symptoms During the Menstrual Cycle and Their Relationship With Physical and Mental Health in Spanish Women of Reproductive Age (Prevalencia de Alteraciones Ovulatorias subclínicas y síntomas Durante el CICLO Menstrual y su relación Con la Salud física y Mental en Mujeres españolas en Edad Reproductiva).","CICLOS","Inclusion Criteria:\n\n* Females\n* Between 18 and 45 years\n* Naturally menstruating.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding.\n* Hormonal contraceptive methods during the 6 months before the study.\n* hysterectomy or ooforectomy.\n* Smoking.","FEMALE","18 Years","45 Years",{"count":21,"type":22},400,"ESTIMATED","5 Months","OBSERVATIONAL","The complexity inherent to the hormonal fluctuations associated with the female menstrual cycle (MC) has contributed, from a methodological perspective in research, to the neglect of women's physiological characteristics and to the silencing and normalization of symptoms linked to different life stages and hormonal environments. The scarce and outdated available data suggest high percentages of women experiencing perimenstrual symptoms, such as premenstrual syndrome or menstrual pain, as well as intermenstrual discomfort. These symptoms not only significantly impair daily activities but, due to their normalization, often lead to the underdiagnosis of other gynecological conditions.\n\nSubclinical ovulatory disturbances-characterized by the suppression of ovarian hormones as an adaptive defense mechanism against various environmental stressors-are also frequently underdiagnosed. These disturbances typically do not affect MC length, making them difficult to detect, and although the process is reversible, it may initiate irreversible consequences for certain tissues, such as bone mass loss. However, neither women nor their educational, occupational, or healthcare environments appear to have the resources and\u002For knowledge required to adequately address these issues.\n\nAll of this may compromise women's rights to adequate sexual and reproductive health and to a dignified quality of life, as recognized under the second line of Axis 4, \"Effective Rights for All Women,\" of the Strategic Plan for Effective Equality between Women and Men 2022-2025. Therefore, the aims of this multicenter project-carried out by a multidisciplinary research team from seven Spanish universities and three international institutions-are to describe the prevalence of symptoms and alterations related to the MC in women of reproductive age and to identify their associations with physical and mental health.\n\nTo accomplish this, an observational study will be conducted in a large sample of women of reproductive age, including multiple symptom and perceived-health questionnaires and ovulation monitoring. In addition, in a subsample of participants, bone mineral density will be assessed, blood levels of sex hormones will be monitored, and an innovative analysis of health biomarkers (glycemic and lipid profile, and inflammation) from menstrual blood will be included. This will be complemented by a qualitative study of experiences related to MC-associated symptoms and alterations, using in-depth interviews and thematic content analysis.\n\nThe findings of this project are expected to support various dissemination and educational actions, justify the design of more inclusive educational and healthcare policies, and enhance the understanding of women's needs, ultimately contributing to improved symptom management and quality of life.",[27,28,29,30,31,32],"Menstrual Cycle","Menstrual Distress (Dysmenorrhea)","Premenstrual Syndrome","Abnormal Uterine Bleeding (AUB)","Ovulation Disorder","Perceived Health Status","RECRUITING","2026-07-08",{"date":36,"type":37},"2026-07-13","ACTUAL",{"date":39,"type":37},"2026-01-21",{"date":41,"type":22},"2026-12",{"name":43,"class":44},"Universidad Rey Juan Carlos","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":45},"100587930","le--cc-vs-le-for-ovulation-induction-100587930","NCT06934785","LE + CC vs. LE for Ovulation Induction","The Combination of Letrozole (LE) and Clomiphene Citrate (CC) or LE Alone for Ovulation Induction in Women With WHO Group II\u002FIV Ovulatory Disorders: A Randomized Controlled Trial","COLA","Inclusion Criteria:\n\n* Women 18-40 years of age\n* Having WHO II\u002FIV ovulatory disorders (length of cycle \\\u003C 21 or \\> 35 days or having \\\u003C 8 cycles per year)\n* Progressive motility (PR) ≥ 32%, sperm concentration ≥ 5 million\u002Fml, total progressive motility sperm count \\> 5 million (World Health Organization, 2021)\n* Written informed consent.\n* Not participating in other studies.\n\nExclusion Criteria:\n\n* Untreated thyroid disease; Thyroid disease is suspected if patients have one of these (Bednarczuk et al., 2021); TSH ≥4 mIU\u002FL or TSH ≥2.5mIU\u002FL and TPOAb (+) or TSH \\\u003C0.1mIU\u002FL\n* Untreated hyper-prolactinemia; Hyperprolactinemia is suspected if patients have prolactinemia concentration \\>50 ng\u002FmL (The sample is collected after an overnight fast, at least 2 hours after waking up, ensuring that venipuncture does not cause excessive stress.)\n* Allergy or having contraindications to LE or CC;\n* Unilateral or Bilateral fallopian tube blockage (HSG, HyFoSy or surgery confirmation)\n* Untreated endometrial abnormalities include endometrial hyperplasia, intrauterine adhesions, endometrial polyp, or chronic endometritis.\n* Uterine abnormalities include leiomyomas L0, L1, or L2; severe adenomyosis; congenital uterine abnormalities, include didelphus, arcuate, unicornuate, bicornuate, septate.","40 Years",{"count":56,"type":22},600,"INTERVENTIONAL",[59],"NA","This randomized controlled trial (RCT) aims to evaluate whether, in infertile women with WHO II\u002FIV ovulatory disorders, a combination of letrozole (LE) and clomiphene citrate (CC) compared to LE alone, result in higher live birth rates.\n\nThe study is designed as an open-label, multicenter RCT across six fertility clinics in Vietnam. Participants will be randomized into two groups: (1) LE + CC , (2) LE alone. The primary outcome measure is the live birth rate after one treatment cycle. Based on prior data, the live birth rate for IUI in letrozole cycles is estimated at 12%. To detect a 10% increase in live birth rates with CC, 436 couples are needed (α = 0.05, power = 80%). Additionally, the live birth rate after IUI with LE-induced ovulation is approximately 18.7% (Diamond et al., 2015). To detect a 10% increase with CC, 560 couples are required (α = 0.05, power = 80%). Considering a 5% loss to follow-up and protocol deviations, the study plans to recruit 600 participants (150 per arm).",[62,63,31,64],"Letrozole","Clomiphene Citrate","Ovulation Induction","2025-09-04",{"date":67,"type":37},"2025-09-11",{"date":69,"type":37},"2025-04-28",{"date":71,"type":22},"2027-06-30",{"name":73,"class":44},"Mỹ Đức Hospital"]